ReviewOncogene2000
Pharmaceutical intervention in the JAK/STAT signaling pathway.
Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Measles contributes to rheumatoid arthritis: evidence from pathway and network analyses of genome-wide association studies.PloS one · 2013Pooled it
- Management of disease-modifying therapies in multiple sclerosis and comorbid rheumatoid arthritis.Neurological research and practice · 2025Review
- Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities.Cancers · 2023Review
- Pancreatic Cancer: Beyond Brca Mutations.Journal of personalized medicine · 2022Review
- Anti-inflammatory effects of miR-150 are associated with the downregulation of STAT1 in macrophages following lipopolysaccharide treatment.Experimental and therapeutic medicine · 2021Article
- Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells.PloS one · 2020Article
- Calycosin-7-O-β-D-glucoside attenuates myocardial ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway via the regulation of IL-10 secretion in mice.Molecular and cellular biochemistry · 2020Article
- Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases.Molecules (Basel, Switzerland) · 2018Article
- Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Drugs & aging · 2017Review
- Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.World journal of gastroenterology · 2016Review
- Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.World journal of gastroenterology · 2016Review
- Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Review
- JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.Neoplasia (New York, N.Y.) · 2015Article
- Mogrol represents a novel leukemia therapeutic, via ERK and STAT3 inhibition.American journal of cancer research · 2015Article
- St. John's wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity.Acta diabetologica · 2014Article
- Thymidine phosphorylase inhibits vascular smooth muscle cell proliferation via upregulation of STAT3.Biochimica et biophysica acta · 2012Article
- Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.British journal of cancer · 2012Review
- The effect of erythropoietin on normal and neoplastic cells.Biologics : targets & therapy · 2012Article
- Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway.Pharmaceuticals (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many cytokines exert their effect via the JAK/STAT signal transduction pathway. Due to the medical relevance of many of these cytokines, they are being exploited, either directly, or through antagonists, as therapeutics for a variety of serious diseases. Currently, these therapeutics consist almost entirely of protein products, with all of their attendant drawbacks. Delineation of the signaling mechanisms for the cytokines, however, has allowed the design and implementation of a variety of cell-based and biochemical screens for small molecule mimics or antagonists of these cytokines. Several successful assays will be described along with the advantages of each type of assay. Use of assays of this type should make it possible to discover numerous small molecule cytokine modulators with significant utility in the clinic. Oncogene (2000).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.